“It is your responsibility to be the patient’s advocate,” one expert explained. “We, as the nurses and technologists, have to speak up when we see something that isn’t right.” “It is your responsibility to be the patient’s advocate,” one expert explained. “We, as the nurses and technologists, have to speak up when we see something that isn’t right.” | | |
|
The new drug, VTB-10, previously received the FDA's orphan drug designation in 2024. The new drug, VTB-10, previously received the FDA's orphan drug designation in 2024. | | |
|
More and more care teams are treating BAV stenosis with TAVR instead of surgical aortic valve replacement. Self-expanding and balloon-expandable valves appear to have their own benefits—as well as their own risks. More and more care teams are treating BAV stenosis with TAVR instead of surgical aortic valve replacement. Self-expanding and balloon-expandable valves appear to have their own benefits—as well as their own risks. | | |
|
Transcatheter patent ductus arteriosus (PDA) closure has been a mainstay in congenital interventional cardiology for decades, but changes in the standard of care have resulted in catheter-based treatments overtaking surgical procedures. Transcatheter patent ductus arteriosus (PDA) closure has been a mainstay in congenital interventional cardiology for decades, but changes in the standard of care have resulted in catheter-based treatments overtaking surgical procedures. | | |
|
|
Speaker issues are causing the devices to stop communicating with the user's CGM. Dozens of patient injuries have been reported, and the company is prepping a software update. Speaker issues are causing the devices to stop communicating with the user's CGM. Dozens of patient injuries have been reported, and the company is prepping a software update. | | |
|
Hemodynamic valve deterioration after one year was more common in patients with a small aortic annulus. In fact, receiving a larger valve was linked to a “protective” quality that appeared to help keep the risk of such complications to a minimum. Hemodynamic valve deterioration after one year was more common in patients with a small aortic annulus. In fact, receiving a larger valve was linked to a “protective” quality that appeared to help keep the risk of such complications to a minimum. | | |
|
New ACC/AHA recommendations encourage clinicians to take a proactive approach when managing patients with elevated or high blood pressure. The inclusion of renal denervation in this document represents clear progress for a relatively new technology. New ACC/AHA recommendations encourage clinicians to take a proactive approach when managing patients with elevated or high blood pressure. The inclusion of renal denervation in this document represents clear progress for a relatively new technology. | | |
|
|
The minimally invasive operation, known as AVATAR, is performed through a small incision in the patient’s neck. The minimally invasive operation, known as AVATAR, is performed through a small incision in the patient’s neck. | | |
|
Karen Joynt Maddox, MD, MPH, explained the many ways cardiology's business models are starting to evolve. She also touched on a number of other topics, including AI and the power of prevention. Karen Joynt Maddox, MD, MPH, explained the many ways cardiology's business models are starting to evolve. She also touched on a number of other topics, including AI and the power of prevention. | | |
|
The first coronary DCB to gain FDA approval just received an additional reimbursement that could improve patient access. The first coronary DCB to gain FDA approval just received an additional reimbursement that could improve patient access. | | |
|
|
Greg Piefer, PhD, chief executive and founder of SHINE, a Wisconsin-based radiopharmaceutical company that is building the world’s largest medical isotope production facility in Janesville, Wisconsin, explains progress on the company's fusion reactor that will become the first U.S. commercial supplier of molybdenum-99 in decades. Greg Piefer, PhD, chief executive and founder of SHINE, a Wisconsin-based radiopharmaceutical company that is building the world’s largest medical isotope production facility in Janesville, Wisconsin, explains progress on the company's fusion reactor that will become the first U.S. commercial supplier of molybdenum-99 in decades. | | |
|
The company operates across six countries with plans to enter the U.S., offering its flagship BMVision Kidney, helping to detect malignant lesions in the organ. The company operates across six countries with plans to enter the U.S., offering its flagship BMVision Kidney, helping to detect malignant lesions in the organ. | | |
|
